{"id":20539,"date":"2024-02-02T11:37:55","date_gmt":"2024-02-02T10:37:55","guid":{"rendered":"https:\/\/www.andrewalliance.com\/?p=20539"},"modified":"2024-04-18T15:11:36","modified_gmt":"2024-04-18T13:11:36","slug":"operation-moonshot-accelerating-covid-19-testing-with-lc-ms-ms","status":"publish","type":"post","link":"https:\/\/www.andrewalliance.com\/fr\/press\/operation-moonshot-accelerating-covid-19-testing-with-lc-ms-ms\/","title":{"rendered":"Operation Moonshot: Accelerating COVID-19 Testing with LC-MS\/MS"},"content":{"rendered":"<p>Operation Moonshot featured <a href=\"https:\/\/theanalyticalscientist.com\/techniques-tools\/operation-moonshot-lessons-from-the-landing?xnpe_tifc=4IbDhFxJbI4Nx.blhkU_4ypZhfEWVjQsVuU_O.18bI4uh.VJtIbdbdxA4kQs4ZJLxIQNtfUu4.BN4IQu4dHdOyXX4f4.b.npxDYphFP.hFnj&amp;utm_source=eNews&amp;utm_campaign=Mass%20Spec%20Newsletter%20Week%2049%202023&amp;utm_medium=email\" target=\"_blank\" rel=\"noopener\">theanalyticalscientist.com<\/a><\/p>\n<p>Below is a quick overview of the full article.<\/p>\n<p>In the summer of 2020, the UK&#8217;s Department of Health and Social Care (DHSC) launched Operation Moonshot to support innovative SARS-CoV-2 diagnostic approaches. This collaboration between academia, industry, and the NHS aimed to develop an LC-MS\/MS-based test for detecting low levels of SARS-CoV-2 tryptic peptides. Surprisingly, the project succeeded in creating a viable test within just five months.<\/p>\n<p>Rachel Carling, Director of Newborn Screening and Clinical Lead for Biomedical Sciences at Synnovis, who led the labs in this initiative, shares key lessons from Operation Moonshot.<\/p>\n<ol>\n<li>Collaboration was Crucial: Operation Moonshot&#8217;s success relied on the synergy between academia, industry, and the NHS. Academia rapidly developed a specialized mass spectrometry method, industry provided advanced technology and support, and the NHS optimized and validated the method for UKAS accreditation.<\/li>\n<li>Choosing Mass Spec: Despite initial concerns about mass spectrometry&#8217;s sensitivity compared to PCR, the team favored it for its ability to detect SARS-CoV-2 peptides while maintaining high throughput and adaptability to handle variants.<\/li>\n<li>Overcoming Challenges: Balancing sensitivity and speed during analysis was a challenge, but the introduction of immunocapture reagents and the Andrew+ pipetting robot streamlined the process.<\/li>\n<li>Key Lessons: Operation Moonshot emphasized the value of collaboration, advanced technology, automation, and dedicated development time. Post-pandemic, the &#8220;triplex&#8221; approach involving academia, industry, and the NHS should continue. Additionally, investing in mass spectrometry and pre-analysis within the NHS offers multiple benefits.<\/li>\n<li>Preparing for Future Pandemics: The experience gained from Operation Moonshot has improved preparedness for future pandemics. Lessons learned include better management of rapidly changing plans and effective communication.<\/li>\n<li>The Future of Clinical Testing: Operation Moonshot has expanded the possibilities of routine clinical labs, showcasing mass spectrometry&#8217;s potential for peptide analysis. This legacy holds promise for numerous clinical testing advancements.<\/li>\n<\/ol>\n<p>In conclusion, Operation Moonshot&#8217;s swift development of an LC-MS\/MS-based COVID-19 test underscores the power of collaboration, mass spectrometry&#8217;s potential in diagnostics, and the importance of healthcare infrastructure investment for pandemic preparedness. These lessons may shape the future of clinical testing and global health readiness.<\/p>","protected":false},"excerpt":{"rendered":"<p>Operation Moonshot featured theanalyticalscientist.com Below is a quick overview of the full article. In the summer of 2020, the UK&#8217;s Department of Health and Social Care (DHSC) launched Operation Moonshot to support innovative SARS-CoV-2 diagnostic approaches. This collaboration between academia, industry, and the NHS aimed to develop an LC-MS\/MS-based test for detecting low levels of [&hellip;]<\/p>\n","protected":false},"author":22,"featured_media":20540,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1335,2],"tags":[],"class_list":["post-20539","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-press"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.andrewalliance.com\/fr\/wp-json\/wp\/v2\/posts\/20539","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.andrewalliance.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.andrewalliance.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.andrewalliance.com\/fr\/wp-json\/wp\/v2\/users\/22"}],"replies":[{"embeddable":true,"href":"https:\/\/www.andrewalliance.com\/fr\/wp-json\/wp\/v2\/comments?post=20539"}],"version-history":[{"count":0,"href":"https:\/\/www.andrewalliance.com\/fr\/wp-json\/wp\/v2\/posts\/20539\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.andrewalliance.com\/fr\/wp-json\/wp\/v2\/media\/20540"}],"wp:attachment":[{"href":"https:\/\/www.andrewalliance.com\/fr\/wp-json\/wp\/v2\/media?parent=20539"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.andrewalliance.com\/fr\/wp-json\/wp\/v2\/categories?post=20539"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.andrewalliance.com\/fr\/wp-json\/wp\/v2\/tags?post=20539"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}